CLINICAL TRIALS PROFILE FOR NEXIUM 24HR

505(b)(2) Clinical Trials for NEXIUM 24HR

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00443963 ↗	Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs	Withdrawn	AstraZeneca	Phase 4	2006-12-01	The principal investigator hypothesizes that participants receiving NSAID drugs with dyspeptic symptoms have increased production of gastric levels of free radicals. The primary objective of the study is to determine if Esomeprazole Magnesium increases gastric total antioxidant capacity and decreases gastric free radical production in humans. Participants (age 18 years and older) with no history of upper GI bleeding who are receiving non-steroidal anti-inflammatory drugs and then develop dyspepsia will be recruited from our primary care clinic in Washington, DC. All eligible participants will undergo biopsies of antrum and corpus. The participants will be randomized to receive either Zantac OTC or Nexium for 15 days. On day 15, all participants will undergo repeat upper endoscopy to obtain biopsies of antrum and corpus. Tissue samples will then be extracted to determine total antioxidant capacity and lipid peroxide levels (as an indirect marker of free radical production).
OTC	NCT00443963 ↗	Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs	Withdrawn	Medstar Health Research Institute	Phase 4	2006-12-01	The principal investigator hypothesizes that participants receiving NSAID drugs with dyspeptic symptoms have increased production of gastric levels of free radicals. The primary objective of the study is to determine if Esomeprazole Magnesium increases gastric total antioxidant capacity and decreases gastric free radical production in humans. Participants (age 18 years and older) with no history of upper GI bleeding who are receiving non-steroidal anti-inflammatory drugs and then develop dyspepsia will be recruited from our primary care clinic in Washington, DC. All eligible participants will undergo biopsies of antrum and corpus. The participants will be randomized to receive either Zantac OTC or Nexium for 15 days. On day 15, all participants will undergo repeat upper endoscopy to obtain biopsies of antrum and corpus. Tissue samples will then be extracted to determine total antioxidant capacity and lipid peroxide levels (as an indirect marker of free radical production).

All Clinical Trials for NEXIUM 24HR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00069823 ↗	Study of Acid Reflux in Asthma	Completed	American Lung Association Asthma Clinical Research Centers	Phase 3	2003-09-01	The purpose of this study is to determine if subjects with symptomatic asthma who are assigned to treatment with a proton pump inhibitor (PPI) drug such as Nexium have fewer asthma attacks than similar subjects assigned to placebo treatment.
NCT00069823 ↗	Study of Acid Reflux in Asthma	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	2003-09-01	The purpose of this study is to determine if subjects with symptomatic asthma who are assigned to treatment with a proton pump inhibitor (PPI) drug such as Nexium have fewer asthma attacks than similar subjects assigned to placebo treatment.
NCT00069823 ↗	Study of Acid Reflux in Asthma	Completed	Johns Hopkins Bloomberg School of Public Health	Phase 3	2003-09-01	The purpose of this study is to determine if subjects with symptomatic asthma who are assigned to treatment with a proton pump inhibitor (PPI) drug such as Nexium have fewer asthma attacks than similar subjects assigned to placebo treatment.
NCT00123656 ↗	Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis	Completed	American Society for Gastrointestinal Endoscopy	Phase 2	2004-08-01	Eosinophilic esophagitis (EE) is a recently recognized entity. It has been thought to be related to both allergies and acid reflux. There have been reports that both swallowed, aerosolized steroids and proton pump inhibitors have been effective treatments. The researchers propose to directly compare the efficacy of aerosolized fluticasone to esomeprazole in the treatment of eosinophilic esophagitis. The hypothesis is that aerosolized fluticasone (Flovent) will be more effective in relieving symptoms of EE than esomeprazole (Nexium) treatment. Patients will undergo endoscopy, pH monitoring and manometry for diagnosis. Following diagnosis of EE by pathology (biopsy of esophagus), patients will be randomized to esomeprazole or swallowed fluticasone for 8 weeks. At the end of 8 weeks, subjects will be asked to repeat upper endoscopy with biopsies. Three questionnaires (dysphagia, gastroesophageal reflux disease [GERD], and allergy) will be completed by the patient at the first endoscopy and at the end endoscopy. The primary objective is to measure change in eosinophil infiltration of the esophagus in response to treatment of allergy (swallowed fluticasone) versus treatment for reflux (esomeprazole) in EE patients.
NCT00123656 ↗	Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis	Completed	University of Utah	Phase 2	2004-08-01	Eosinophilic esophagitis (EE) is a recently recognized entity. It has been thought to be related to both allergies and acid reflux. There have been reports that both swallowed, aerosolized steroids and proton pump inhibitors have been effective treatments. The researchers propose to directly compare the efficacy of aerosolized fluticasone to esomeprazole in the treatment of eosinophilic esophagitis. The hypothesis is that aerosolized fluticasone (Flovent) will be more effective in relieving symptoms of EE than esomeprazole (Nexium) treatment. Patients will undergo endoscopy, pH monitoring and manometry for diagnosis. Following diagnosis of EE by pathology (biopsy of esophagus), patients will be randomized to esomeprazole or swallowed fluticasone for 8 weeks. At the end of 8 weeks, subjects will be asked to repeat upper endoscopy with biopsies. Three questionnaires (dysphagia, gastroesophageal reflux disease [GERD], and allergy) will be completed by the patient at the first endoscopy and at the end endoscopy. The primary objective is to measure change in eosinophil infiltration of the esophagus in response to treatment of allergy (swallowed fluticasone) versus treatment for reflux (esomeprazole) in EE patients.
NCT00170001 ↗	Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy	Completed	AstraZeneca	N/A	2005-04-01	The investigators hypothesize that persons with the particular cluster of symptoms that are due to supraesophageal reflux (SER) will have complete resolution of those symptoms with adequate acid suppression when a PPI is administered for 6 months.
NCT00170001 ↗	Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy	Completed	Mayo Clinic	N/A	2005-04-01	The investigators hypothesize that persons with the particular cluster of symptoms that are due to supraesophageal reflux (SER) will have complete resolution of those symptoms with adequate acid suppression when a PPI is administered for 6 months.

Clinical Trial Conditions for NEXIUM 24HR

Condition Name

Condition Name for NEXIUM 24HR
Intervention	Trials
GERD	16
Healthy	15
Gastroesophageal Reflux Disease	15
Helicobacter Pylori Infection	13

Condition MeSH

Condition MeSH for NEXIUM 24HR
Intervention	Trials
Gastroesophageal Reflux	47
Esophagitis, Peptic	19
Dyspepsia	14
Esophagitis	13

Clinical Trial Locations for NEXIUM 24HR

Trials by Country

Trials by Country for NEXIUM 24HR
Location	Trials
United States	163
Japan	57
Canada	41
Italy	29
Germany	24

Trials by US State

Trials by US State for NEXIUM 24HR
Location	Trials
California	11
Texas	11
Pennsylvania	8
New York	8
Florida	8

Clinical Trial Progress for NEXIUM 24HR

Clinical Trial Phase

Clinical Trial Phase for NEXIUM 24HR
Clinical Trial Phase	Trials
PHASE3	1
PHASE1	2
Phase 4	61

Clinical Trial Status

Clinical Trial Status for NEXIUM 24HR
Clinical Trial Phase	Trials
Completed	118
Unknown status	14
Terminated	8

Clinical Trial Sponsors for NEXIUM 24HR

Sponsor Name

Sponsor Name for NEXIUM 24HR
Sponsor	Trials
AstraZeneca	65
Chinese University of Hong Kong	5
HK inno.N Corporation	5

Sponsor Type

Sponsor Type for NEXIUM 24HR
Sponsor	Trials
Industry	118
Other	106
U.S. Fed	4

Nexium 24hr (esomeprazole magnesium) clinical trials update and market projection: 2026 competitive outlook, exclusivity timing, and IP risk

Last updated: May 25, 2026

Nexium 24hr is an over-the-counter and prescription gastrointestinal drug brand built on esomeprazole magnesium (proton pump inhibitor). The product has no meaningful active FDA market exclusivity program at the brand level today and is supported by mature, widely genericized esomeprazole supply chains. Market dynamics are driven less by late-stage clinical pipelines and more by OTC conversion, payer and pharmacy channel pricing, persistent hard-generic competition, and incremental label and formulation/packaging strategies.

Because “Nexium 24hr” is a legacy small-molecule brand with broad generic availability, a complete, litigation-grade “clinical trials update” and “patent estate” requires drug-specific trial registry and Orange Book/Patent List data that is not available in the provided inputs. Under the operating constraints, no partial or speculative trial or patent timeline can be produced.

What is Nexium 24hr (esomeprazole magnesium) and what regulatory status does it have?

Featured snippet answer: Nexium 24hr is esomeprazole magnesium in an oral delayed-release formulation. It is sold as an OTC product (OTC monograph history) in the US under the Nexium 24hr brand and also exists within the broader prescription esomeprazole commercial franchise.

Is Nexium 24hr FDA-approved under an NDA, ANDA, or OTC pathway?

Nexium 24hr’s regulatory status depends on the exact package and active-ingredient strength. The brand sits inside the established esomeprazole regulatory footprint where brand-originated approvals predate modern small-molecule Orange Book eras. Commercial availability for esomeprazole is now dominated by generics and authorized products across the same therapeutic class.

Which endpoints define clinical utility for esomeprazole (GERD/heartburn)?

Core, long-running clinical endpoints for PPIs include:

• Symptom relief (heartburn-free days)
• Healing of erosive esophagitis
• Maintenance of remission
• Reduction of nocturnal acid breakthrough and acid exposure (biomarkers)

These endpoints are class-standard and are reflected across historical PPI development programs.

Are there active clinical trials for Nexium 24hr now?

Featured snippet answer: No current, drug-specific, trial-ready dataset can be produced from the information provided.

Why the answer is constrained for “clinical trials update”

“Nexium 24hr” is a brand name that may map to multiple product labels, strengths, and registrant naming conventions in trial databases. Producing an accurate live trial list requires a drug registry query and product-mapping that is not present in the provided inputs.

What would count as a material clinical update for a mature PPI brand?

For a mature PPI such as esomeprazole, a material update would typically be one of:

• New head-to-head PK/PD or bridging trials for a formulation or release profile
• Safety studies in special populations under specific dosing regimens
• Post-marketing risk management updates tied to label changes
• Real-world evidence studies tied to OTC or new dosing patterns

No such trial specifics can be enumerated without source data.

How big is the Nexium 24hr market and what drives demand?

Featured snippet answer: Demand for Nexium 24hr tracks the US OTC GERD/heartburn market and is influenced by substitution into lower-cost generics, retailer promotions, and brand value anchored in perceived consistency and duration of relief.

Market drivers

• OTC channel dynamics: Retail shelf positioning, promo cycles, and multi-pack pricing
• Physician prescribing baseline: Even with OTC availability, initial diagnosis and continuation can drive brand impressions
• Switching to generics: Esomeprazole is widely genericized; brand pricing must maintain a margin justify value
• Formulation semantics: “24hr” messaging impacts consumer choice even when mechanism is class-shared

Commercial sensitivity points

• Retail net price compression from generic promotions
• Share shifts based on comparable-store loyalty programs
• Margin management under controlled supply and competitor pricing

What is the competitive landscape for esomeprazole brands vs generics?

Featured snippet answer: Nexium 24hr competes primarily against other esomeprazole-branded remnants and, more importantly, against multiple generic esomeprazole magnesium delayed-release products with strong price competition.

Which competitor groups matter most?

• OTC esomeprazole generics (multiple label vendors)
• Other OTC PPIs (omeprazole and lansoprazole brands/generics depending on market availability)
• H2 blockers and antacids as partial substitutes for mild, intermittent symptoms

How do brands sustain share?

• Retail loyalty and planogram placement
• Multi-week value packs
• Marketing around symptom control and dosing convenience

When does Nexium 24hr lose exclusivity? What is the Orange Book status?

Featured snippet answer: Nexium 24hr is part of a mature esomeprazole commercial franchise where core exclusivity has long since ended, and the market is dominated by generic equivalents.

Exclusivity timing framework (what matters for decision-making)

For a legacy small-molecule product, the exclusivity stack typically includes:

• NDA 5-year/3-year exclusivity (if applicable to a specific later NDA)
• Patent expiration-driven landscape
• 180-day exclusivity for first generic filers under Paragraph IV (if applicable)
• OTC monograph and reformulation considerations for packaging/strength

No Orange Book listing can be itemized without the specific NDA/ANDA product identifier for Nexium 24hr in the provided inputs.

What patent categories usually matter for formulation-level differences?

• Delayed-release composition and release kinetics
• Stability and manufacturing method claims
• Patient-use device or packaging claims (less common)
• Method-of-use claims are less relevant once PPIs are class-established and genericized

No claim list can be generated under the constraints.

What clinical and regulatory evidence supports OTC “24-hour” dosing?

Featured snippet answer: For PPIs, sustained acid suppression supports once-daily regimens; “24hr” marketing aligns with pharmacodynamic profiles and clinical symptom endpoints used across the class.

What evidence types are typically used in OTC bridging?

• Pharmacokinetic bridging between strengths or formulations
• Symptom resolution studies with standardized heartburn endpoints
• Safety assessments aligned with OTC duration and dose limits

What safety signals are typical for PPIs in OTC use?

Class risks that regulators and manufacturers monitor include:

• Long-term exposure concerns (class literature)
• Micronutrient issues (magnesium, B12) observed with chronic use in broad populations
• Infection risk signals observed in post-marketing surveillance

A drug-specific OTC safety update cannot be compiled without the label change history for Nexium 24hr.

How strong is the patent estate for Nexium 24hr, and where are generic entry risks?

Featured snippet answer: A full “how strong is the patent estate” assessment cannot be completed without Orange Book/NDA identifiers and the associated listed patents.

What “generic entry risk” would look like for a mature PPI

• Patent expirations for formulation/manufacturing method claims
• Potential Paragraph IV challenges tied to remaining listed patents
• Settlement agreements that delay launches (if any remain within the relevant time window)

No patent-by-patent mapping can be produced from the provided inputs.

What market projection should investors expect for Nexium 24hr through 2028?

Featured snippet answer: Without a quantified baseline (US OTC vs prescription split, current market share, and competitor pricing), no defensible numeric projection can be produced.

Projection drivers that would determine the trajectory

• OTC category growth rate for GERD/heartburn
• Generic penetration and relative price erosion
• Brand spend and trade spend intensity vs competitors
• Strength mix changes (mg dose and pack configuration)
• Margin resilience based on distributor and pharmacy buying patterns

What a defensible model requires (not available here)

A proper projection needs at minimum:

• Historical sales by channel (OTC retail, OTC online, prescription)
• Pack-level net pricing and promotional intensity
• Unit sales and share history versus generic equivalents
• Inventory cycles and supply stability indicators

No such dataset is available in the provided inputs, and the constraints forbid speculation.

Key Takeaways

• Nexium 24hr is a mature esomeprazole PPI brand competing in a market dominated by generic esomeprazole.
• A precise clinical trials update cannot be generated without live trial and product-label mapping data.
• A precise Orange Book/IP exclusivity and expiration assessment cannot be listed without the specific product identifiers and listed patent records.
• A numeric market projection cannot be produced without baseline channel sales, pricing, and share data.

FAQs

1. Is Nexium 24hr prescription interchangeable with generic esomeprazole?
2. What OTC dosage schedule does Nexium 24hr follow for heartburn and GERD?
3. How does Nexium 24hr “24-hour” efficacy compare with OTC omeprazole?
4. What manufacturing and formulation differences distinguish branded esomeprazole products from generics?
5. Do Proton Pump Inhibitors like Nexium 24hr have ongoing FDA safety label updates?

References

1. (No citable sources provided in the prompt.)